Skip to main content

Closed

CTOR: Citius Oncology, Inc. Stock Analysis | finqOS

Healthcare · Drug Manufacturers - General

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+0.0% / yr

Operating margin-775.6%

ROIC-103.9%

Financially safe

Stretched

Debt / equity0.11×

Interest coverage-146.6×

Current ratio0.50×

Citius Oncology, Inc.

CTORNASDAQ Global Market·USD·Closed

Citius Oncology, Inc.

CTORNASDAQ·USD·Closed

$0.59

+3.22%

$0.59

+$0.02 (3.22%)

52W Range

6thpctl

Volume

0.55×avg

Mkt Cap

55.07MUSD

P/E

-1.3TTM

Div Yield

–ann

52W Range

6thpctl

Volume

0.55×avg

Market Cap

55.07MUSD

P/E Ratio

-1.3TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings